329 related articles for article (PubMed ID: 847240)
21. Evaluation of vaginal delivery systems containing 15[s]15-methyl PGF2alpha methyl ester.
Spilman CH; Beuving DC; Forbes AD; Roseman TJ; Larion LJ
Prostaglandins; 1976; 12 Suppl():1-16. PubMed ID: 968060
[TBL] [Abstract][Full Text] [Related]
22. [Effect of 15-methyl-prostaglandin F2 alpha used for dilating the cervix uteri before abortion on endogenous prostaglandin F2 alpha synthesis].
Goncharova VN; Morozova MS; Razina LG; Manuilova IA; Murashko LE
Akush Ginekol (Mosk); 1981 Dec; (12):37-8. PubMed ID: 6950671
[TBL] [Abstract][Full Text] [Related]
23. Interruption of pregnancy by prostaglandin 15-methyl F2alpha.
Bolognese RJ; Corson SL
Fertil Steril; 1975 Jul; 26(7):695-9. PubMed ID: 1149900
[TBL] [Abstract][Full Text] [Related]
24. Termination of early gestation with a single vaginal suppository of (15S)-15-methyl-prostaglandin F2alpha methyl ester.
Roy S; Brenner PF; Marrs RP; Mishell DR
Contraception; 1980 Aug; 22(2):137-52. PubMed ID: 7449379
[TBL] [Abstract][Full Text] [Related]
25. Vaginal administration of 15-methyl-PGF2 alpha methyl ester for preoperative cervical dilatation. Task force on prostaglandins for fertility regulation. The World Health Organization.
Contraception; 1981 Mar; 23(3):251-9. PubMed ID: 7016432
[TBL] [Abstract][Full Text] [Related]
26. Midtrimester abortion induced by serial intravaginal administration of prostaglandin E2 suppositories in conjunction with a contraceptive diaphragm.
Lauersen NH; Wilson KH
Prostaglandins; 1975 Jul; 10(1):139-50. PubMed ID: 1153798
[TBL] [Abstract][Full Text] [Related]
27. Termination of early gestation with 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2.
Brenner PF; Marrs RP; Roy S; Mishell DR
Contraception; 1982 Sep; 26(3):261-77. PubMed ID: 6184197
[TBL] [Abstract][Full Text] [Related]
28. Serum hormone levels in women undergoing abortion with intra-amniotic, extra-amniotic or intra-muscular administration of 15(S) 15-methyl-prostaglandin F2alpha.
Puri CP; Rahman SA; Jain AK; Bhaduri R; Singh CM; Hingorani V; Laumas KR
Prostaglandins; 1976 May; 11(5):905-23. PubMed ID: 935519
[TBL] [Abstract][Full Text] [Related]
29. The current status of prostaglandins as abortifacients.
Brenner WE
Am J Obstet Gynecol; 1975 Oct; 123(3):306-28. PubMed ID: 810025
[TBL] [Abstract][Full Text] [Related]
30. Abortifacient effect and uterine cervix-dilating action of 16, 16-dimethyl trans delta 2 PGE1 methyl ester (ONO 802) in the form of a vaginal suppository (a randomized, double-blind, controlled study in the second trimester of pregnancy).
Sakamoto S; Satoh K; Nishiya I; Kunimoto K; Chimura T; Oda T; Takeuchi S; Satoh Y; Iizuka R; Kobayashi T; Takagi S; Yoshida T; Tomoda Y; Ninagawa T; Kurachi K; Tanizawa O; Tojo S; Mochizuki M; Maeda K; Tominaga Y; Torigoe T; Koresawa M; Taki I; Hamada T
Prostaglandins Leukot Med; 1982 Sep; 9(3):349-61. PubMed ID: 6752961
[TBL] [Abstract][Full Text] [Related]
31. Early pregnancy-abortion model using sulprostone.
Fleischer A; Schulman H; Blattner P; Jagani N; Fayemi A
Prostaglandins; 1982 May; 23(5):643-55. PubMed ID: 7122906
[TBL] [Abstract][Full Text] [Related]
32. Midtrimester intra-aminotic administration of prostaglandin F2alpha in combination with an hyperosmolar urea solution: effect upon plasma levels of estradiol, progesterone, and human placental lactogen (HPL).
Sher G; Katz M
Acta Obstet Gynecol Scand; 1978; 57(3):223-5. PubMed ID: 665164
[TBL] [Abstract][Full Text] [Related]
33. Outpatient postconceptional fertility control with vaginally administered 15(S) 15-methyl-PGF2alpha-methyl ester.
Bygdeman M; Martin JN; Eneroth P; Leader A; Lundström V
Am J Obstet Gynecol; 1976 Mar; 124(5):495-8. PubMed ID: 1258906
[TBL] [Abstract][Full Text] [Related]
34. Development of a vaginal suppository suitable for single administration for interruption of second trimester pregnancy.
Bygdeman M; Ganguli A; Kinoshita K; Lundström V; Green K; Bergström S
Contraception; 1977 Feb; 15(2):129-41. PubMed ID: 837687
[No Abstract] [Full Text] [Related]
35. Methods to determine success of attempts to terminate early gestation pregnancies with prostaglandin vaginal suppositories.
Brenner PF; Marrs RP; Roy S; Mishell DR
Contraception; 1983 Aug; 28(2):111-24. PubMed ID: 6196152
[TBL] [Abstract][Full Text] [Related]
36. Low-dose vaginal 15 methyl prostaglandin F2 alpha for cervical dilatation prior to vacuum curettage abortion.
Niloff JM; Stubblefield PG
Am J Obstet Gynecol; 1982 Mar; 142(5):596-7. PubMed ID: 7036748
[TBL] [Abstract][Full Text] [Related]
37. Suppression of concentration of endometrial prostaglandin in early intra-uterine and ectopic pregnancy in women.
Abel MH; Smith SK; Baird DT
J Endocrinol; 1980 Jun; 85(3):379-86. PubMed ID: 7411005
[TBL] [Abstract][Full Text] [Related]
38. Vaginally administered PGF2alpha for cervical dilatation in nulliparas prior to suction curettage.
Brenner WE; Dingfelder JR; Staurovsky LG; Hendricks CH
Prostaglandins; 1973 Dec; 4(6):819-36. PubMed ID: 4783581
[TBL] [Abstract][Full Text] [Related]
39. Termination of second trimester pregnancy with a long-acting vaginal pessary containing 15-methyl-PGF2 alpha methyl ester.
Int J Gynaecol Obstet; 1983 Apr; 21(2):159-65. PubMed ID: 6136437
[TBL] [Abstract][Full Text] [Related]
40. Luteolytic and abortifacient effects of serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha in early pregnancy.
Lauersen NH; Wilson KH
Am J Obstet Gynecol; 1976 Feb; 124(4):425-9. PubMed ID: 1251863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
